Ido Schoenberg, MD is the Chairman and CEO of Amwell (NYSE: AMWL), one of the largest digital health and telehealth platforms in the world. A trained physician turned serial healthcare technology entrepreneur, Schoenberg co-founded Amwell (originally American Well) in 2006 alongside his brother Roy Schoenberg. He led the company through its landmark NYSE IPO in 2020 and has steered it through a major strategic transformation, divesting non-core assets and targeting cash flow breakeven by Q4 2026. Under his leadership, Amwell’s platform connects millions of patients with healthcare providers through secure digital care delivery.
Read on to discover Amwell CEO email address, Ido Schoenberg net worth in 2026, salary and compensation, career history, wife & family, and more.
Ido Schoenberg – Quick Facts
| Ido Schoenberg — At a Glance | |
|---|---|
| Full Name | Ido Schoenberg, MD |
| Position | Chairman & Chief Executive Officer |
| Company | Amwell (NYSE: AMWL) |
| Age | ~62 years (born c. 1964) |
| Education | MD, Sackler School of Medicine, Tel Aviv University |
| Net Worth (Est.) | $15–20 million |
| Total Compensation (2022) | $16.16 million |
| Base Salary | ~$798,000 |
| CEO Since | Co-Founded 2006; sole CEO since 2024 |
| Previous Role | Chief Business Strategy Officer, TriZetto Group |
| Headquarters | Boston, Massachusetts |
| Email Domain | @americanwell.com / @amwell.com |
Amwell Competitors
Amwell operates in the rapidly growing digital health and telehealth industry. The key competitors of Amwell include:
- Teladoc Health (NYSE: TDOC) – The largest publicly traded telehealth company by revenue
- MDLive (acquired by Cigna/Evernorth) – Virtual care platform for health plans and employers
- Included Health (formerly Grand Rounds & Doctor on Demand) – Integrated virtual and in-person care navigation
- Doxy.me – Telemedicine platform popular with independent providers
- Zoom Video Communications – Zoom for Healthcare offering telehealth capabilities
- Epic Systems – MyChart telehealth integration within major health systems
- Veradigm (Allscripts) – Healthcare IT solutions including virtual care
- Doximity (NYSE: DOCS) – Physician platform with telehealth features
Ido Schoenberg Net Worth 2026 – Amwell CEO Salary
As of 2026, Ido Schoenberg’s net worth is estimated at approximately $15–20 million, based on his disclosed stock holdings in Amwell and historical compensation. According to SEC filings, Schoenberg holds approximately 138,895 shares of AMWL stock. Given Amwell’s current share price in the $4–5 range, his equity stake is valued at roughly $600,000–$700,000, though his total net worth reflects years of accumulated compensation and prior entrepreneurial ventures including iMDSoft and CareKey.
Amwell CEO Compensation Breakdown (FY2022)
| Component | Amount (USD) | Share |
|---|---|---|
| Base Salary | $797,800 | 4.9% |
| Cash Compensation (Total) | $1,360,101 | 8.4% |
| Equity Awards (Stock/Options) | $14,645,000 | 90.6% |
| Other Compensation | $156,129 | 1.0% |
| TOTAL | $16,161,230 | 100% |
Key Insight: Over 90% of Dr. Schoenberg’s compensation is equity-based, aligning his financial interests closely with Amwell’s stock performance and long-term shareholder value. His base salary of approximately $798,000 represents less than 5% of his total pay package.
Amwell Net Worth 2026 – Is Amwell Profitable?
Amwell is not yet profitable but has made significant strides toward financial sustainability. In fiscal year 2025, the company reduced both its net loss and adjusted EBITDA loss by approximately $100 million each compared to the prior year, driven by disciplined cost management and a more focused operating model. Management has set a target of achieving positive cash flow from operations by Q4 2026.
Amwell Financial Summary
| Metric | FY2025 | FY2024 | YoY Change |
|---|---|---|---|
| Revenue | $249.3M | $259.7M | ▼ -4.0% |
| Subscription Revenue (% of Total) | 53% | 45% | ▲ +8 pts |
| Q4 Revenue | $55.3M | $71.0M | ▼ -22.1% |
| Q4 Gross Margin | 51% | — | — |
| Net Loss Reduction | ~$100M improvement | — | ▲ Significant |
| Adj. EBITDA (Q4) | $(10.3M) | — | ▲ Improving |
| Market Cap (Mar 2026) | ~$75–90M | — | |
| Stock Ticker | NYSE: AMWL | — | |
2026 Guidance: Amwell expects full-year 2026 revenue of $195–$205 million, with AMG visits of 1.32–1.37 million. The company targets an adjusted EBITDA loss of just $18–$24 million and aims to reach cash flow breakeven by Q4 2026.
Amwell CEO Email Address | Ido Schoenberg Contact
Below are the official contact details and social media profiles for Amwell CEO Ido Schoenberg:
| Contact Information | |
|---|---|
| Email Domain | @americanwell.com (also @amwell.com) |
| Investor Relations | [email protected] |
| Corporate HQ | 75 State Street, 26th Floor, Boston, MA 02109 |
| Phone | (617) 204-3500 |
| Ido Schoenberg – Chairman and CEO at Amwell | |
| Website | business.amwell.com |
Early Life & Education
Ido Schoenberg was born around 1964 in Israel, where he grew up in a small village outside Jerusalem. As a native Israeli citizen, Schoenberg completed mandatory military service in the Israel Defense Forces (IDF) before pursuing higher education — a formative experience that instilled discipline and leadership skills that would shape his entrepreneurial career.
After completing his military service, Schoenberg enrolled at Tel Aviv University’s Sackler School of Medicine, one of Israel’s most prestigious medical schools. He earned his Doctor of Medicine (MD) degree, gaining deep knowledge of healthcare systems, clinical workflows, and patient care. However, rather than pursuing a traditional clinical practice, Schoenberg was drawn to the intersection of medicine and technology, recognizing the enormous potential for innovation in healthcare delivery.
His medical training gave him a unique vantage point as a technology entrepreneur — a physician’s understanding of clinical needs combined with an engineer’s approach to solving problems at scale. This dual perspective would become the foundation of every company he built, from iMDSoft to Amwell.
Career History
Ido Schoenberg’s career is defined by a serial entrepreneurial drive focused exclusively on healthcare technology. Over three decades, he has founded, led, and scaled multiple healthcare IT companies, each one building on the insights of the last.
Ido Schoenberg Career Timeline
| Period | Role | Company |
|---|---|---|
| 1996 | Co-Founder | iMDSoft |
| 2001 | Chief Executive Officer | CareKey Inc. |
| 2001–2006 | Chief Business Strategy Officer | TriZetto Group |
| 2006 | Co-Founder | American Well (Amwell) |
| 2006–2024 | Co-Chairman & Co-CEO | Amwell |
| 2020 | Led Company IPO (NYSE: AMWL) | Amwell |
| 2024–Present | Chairman & CEO (sole) | Amwell |
iMDSoft (1996)
In 1996, Schoenberg co-founded iMDSoft with his wife Phyllis Gotlib. The company developed enterprise software that automated hospital critical care units, digitizing clinical workflows in ICUs and operating rooms. Under his leadership, iMDSoft grew from a startup into a multinational company with installations across the United States, Europe, and East Asia. The company became a market leader in clinical information systems for critical care — an impressive feat in the late 1990s when hospital IT adoption was still in its infancy.
CareKey & TriZetto Group (2001–2006)
In 2001, Schoenberg joined CareKey Inc. as CEO and successfully led the company through its acquisition by the TriZetto Group, a major healthcare IT firm focused on payer administration technology. Following the acquisition, he served as TriZetto’s Chief Business Strategy Officer until 2006, where he helped shape the company’s strategic direction in healthcare information technology. TriZetto was later acquired by Cognizant Technology Solutions in 2014 for $2.7 billion.
Founding Amwell (2006)
In the summer of 2006, Schoenberg and his brother Roy Schoenberg, MD, MPH co-founded American Well (later rebranded to Amwell). The brothers shared a vision of leveraging technology to connect patients with physicians remotely — years before “telehealth” became a household word. Their physician backgrounds gave them credibility with healthcare providers and health systems skeptical of virtual care.
The brothers served as co-CEOs for nearly two decades, with Ido focusing on corporate strategy and vision while Roy managed product and operations. Together they built Amwell into one of the largest digital health platforms, serving major health systems, health plans, and government entities across the globe.
CEO Role at Amwell
In 2024, Ido Schoenberg became the sole Chairman and CEO of Amwell after Roy Schoenberg transitioned to the role of Executive Vice Chairman of the Board. This leadership consolidation came at a critical juncture as the company embarked on a strategic transformation to focus on its core technology platform.
Key milestones under Schoenberg’s CEO leadership include:
- IPO (September 2020) – Led Amwell to its initial public offering on the NYSE under ticker AMWL, raising significant capital during the pandemic-driven surge in telehealth demand
- Platform Strategy (2024–2025) – Executed a strategic pivot to focus on Amwell’s technology platform, divesting non-core assets including the sale of the Amwell Psychiatric Care (APC) business
- Cost Transformation – Reduced net loss and adjusted EBITDA loss by approximately $100 million each in FY2025
- Payer Renewals – Secured more than 15 payer contract renewals in 2025, representing the vast majority of existing payer subscription revenue
- AI Integration – Championed the integration of artificial intelligence into Amwell’s platform to enhance care delivery and clinical efficiency
- Path to Profitability – Set a clear target for positive cash flow from operations by Q4 2026
Leadership & Achievements
Dr. Ido Schoenberg is widely recognized as one of the pioneers of digital health and telehealth technology. His contributions to the industry span over two decades and include:
- Telehealth Pioneer – Co-founded Amwell years before telehealth became mainstream, helping establish the regulatory and technological framework for virtual care delivery
- COVID-19 Response – Amwell’s platform played a critical role during the COVID-19 pandemic, enabling healthcare systems to continue providing care when in-person visits were impossible
- Israeli American Council – Active speaker and participant in the IAC, advocating for Israeli-American entrepreneurship and innovation
- Healthcare IT Thought Leader – Frequent speaker at major healthcare and technology conferences including HIMSS, Health 2.0, and the TD Securities Healthcare Conference
- Serial Entrepreneur – Successfully founded or led four healthcare technology companies (iMDSoft, CareKey, TriZetto, Amwell), with multiple successful exits
- Physician-CEO – One of few physician-founders leading a publicly traded digital health company, bringing clinical credibility to technology decisions
Notable Quote: In Amwell’s Q4 2025 earnings call, Schoenberg stated: “We successfully sharpened our focus on our tech platform, validated strong market demand, and meaningfully improved both our efficiency and cost structure.”
Personal Life
Ido Schoenberg is an Israeli-American who grew up in a village outside Jerusalem before moving to the United States to build his career in healthcare technology. He is based in the Boston, Massachusetts area, near Amwell’s corporate headquarters.
Schoenberg’s wife, Phyllis Gotlib, co-founded iMDSoft with him in 1996, making them one of healthcare technology’s notable entrepreneurial couples. Their shared professional background in healthcare IT laid the groundwork for Schoenberg’s later ventures.
His brother, Roy Schoenberg, MD, MPH, co-founded Amwell with him and served as Co-CEO until 2024. The Schoenberg brothers are one of the most prominent sibling partnerships in healthcare technology, having worked together for nearly two decades to build Amwell into a publicly traded company. Roy now serves as Executive Vice Chairman of the Board.
Despite his prominent position in healthcare technology, Schoenberg maintains a relatively private personal life. He is known among colleagues for his deep passion for healthcare innovation and his conviction that technology can fundamentally improve how care is delivered to patients worldwide.
Ido Schoenberg Salary & Net Worth Summary
Below is a summary of Ido Schoenberg’s estimated net worth and compensation:
| Category | Details |
|---|---|
| Estimated Net Worth (2026) | $15–20 million |
| Primary Wealth Source | Amwell equity, historical compensation, prior ventures |
| AMWL Shares Held | ~138,895 shares |
| Total Compensation (FY2022) | $16,161,230 |
| Base Salary | ~$798,000 |
| Equity Awards (FY2022) | $14,645,000 |
| AMWL Stock Price (Mar 2026) | ~$4–5 per share |
Frequently Asked Questions (FAQ)
Who is the CEO of Amwell?
The current CEO of Amwell is Dr. Ido Schoenberg, who co-founded the company in 2006 with his brother Roy Schoenberg. Ido became the sole Chairman and CEO in 2024 when Roy transitioned to Executive Vice Chairman.
What is Ido Schoenberg’s net worth?
Ido Schoenberg’s net worth is estimated at $15–20 million as of 2026. His wealth is derived from his Amwell stock holdings, years of executive compensation, and prior entrepreneurial ventures including iMDSoft and CareKey.
What is Amwell CEO’s salary?
Ido Schoenberg’s base salary is approximately $798,000. His total compensation in FY2022 was $16.16 million, with over 90% coming from equity awards. The majority of his pay is performance-based and tied to Amwell’s stock price.
What is Amwell CEO’s email address?
Amwell CEO Ido Schoenberg can be reached via the corporate email domain @americanwell.com (also @amwell.com). For investor relations, contact [email protected]. The corporate phone number is (617) 204-3500.
Is Ido Schoenberg a real doctor?
Yes, Dr. Schoenberg holds an MD from Tel Aviv University’s Sackler School of Medicine. However, he chose to focus his career on healthcare technology entrepreneurship rather than clinical practice, co-founding multiple health-tech companies over three decades.
Who co-founded Amwell?
Amwell was co-founded in 2006 by brothers Ido Schoenberg and Roy Schoenberg, both physicians. They served as co-CEOs for nearly two decades before Roy transitioned to Executive Vice Chairman in 2024.
Is Amwell profitable?
Amwell is not yet profitable but has significantly reduced its losses. In FY2025, the company reduced both net loss and adjusted EBITDA loss by approximately $100 million each. Management targets positive cash flow from operations by Q4 2026, with 2026 revenue guidance of $195–$205 million.
What does Amwell do?
Amwell is a digital health and telehealth platform that enables healthcare providers, health systems, health plans, and government entities to deliver care digitally. The platform connects patients with physicians through secure video consultations, supports remote patient monitoring, and integrates AI-powered tools for clinical efficiency.
Article last updated: March 2026
Disclaimer: All information presented in this article has been compiled from publicly available sources, including SEC filings, official company press releases, and reputable news outlets. This content is provided for informational purposes only and does not constitute financial or investment advice.